세계의 간성뇌증 시장 보고서(2025년)

Hepatic encephalopathy is a condition characterized by a decline in brain function resulting from severe liver disease. It is a reversible syndrome of impaired brain function in patients with advanced liver diseases. Treating hepatic encephalopathy (HE) involves managing the underlying liver disease, reducing ammonia levels in the blood and addressing neurological symptoms.

The main drug types of hepatic encephalopathy are antibiotics, laxatives, l-ornithine, l-aspartate and others. Antibiotics are a class of medications that are used to treat bacterial infections and helps lower the overall ammonia load in the body, which can contribute to the neurological symptoms associated with hepatic encephalopathy. The various route of administration including oral, intravenous and rectal which are distributed through various distribution channels such as hospital pharmacies, retail pharmacies and online pharmacies.

The hepatic encephalopathy market research report is one of a series of new reports from The Business Research Company that provides hepatic encephalopathy market statistics, including hepatic encephalopathy industry global market size, regional shares, competitors with a hepatic encephalopathy market share, detailed hepatic encephalopathy market segments, market trends and opportunities and any further data you may need to thrive in the hepatic encephalopathy industry. This hepatic encephalopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatic encephalopathy market size has grown strongly in recent years. It will grow from $1.72 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to prevalence of liver diseases, growing awareness about hepatic encephalopathy, government initiatives, increasing new liver therapies.

The hepatic encephalopathy market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing ageing population, surge in treatment options, rising expenditure on healthcare infrastructure, investments on hepatic encephalopathy treatments. Major trends in the forecast period include launch of emerging therapies, research and clinical trials, advances in liver transplantation, pharmaceutical innovations, advances in nutrition and dietary management, adption of telemedicine and remote monitoring.

The increasing prevalence of liver diseases is expected to drive the growth of the hepatic encephalopathy market in the coming years. Liver disease refers to any condition that affects the liver and impairs its functionality. Treatments for liver diseases, such as those for hepatic encephalopathy, can help alleviate symptoms, slow the progression of the disease, improve liver function, and reduce the occurrence of hepatic encephalopathy by better managing underlying conditions. This can potentially decrease both the frequency and severity of episodes, improving patients' overall quality of life. For example, in April 2024, the Office for Health Improvement and Disparities, a government department in the UK, reported that hospital admissions for liver disease continued to rise, reaching 155.2 per 100,000 population in the financial year ending 2023, up from 150.6 the previous year. As such, the increasing prevalence of liver diseases is fueling the growth of the hepatic encephalopathy market.

Rising healthcare expenditures are expected to drive the growth of the hepatic encephalopathy market. Healthcare expenditures refer to the total spending on healthcare services, products, and activities over a specific period, which can be measured at the individual, community, national, or global level. Increased healthcare spending can positively affect the availability and development of hepatic encephalopathy treatments by supporting advancements in diagnosis, treatment options, awareness, and patient care. For example, in December 2023, the Centers for Medicare & Medicaid Services, a U.S.-based federal agency, reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, surpassing the 3.2% increase seen in 2021. As a result, the rise in healthcare expenditures will contribute to the growth of the hepatic encephalopathy market.

Prominent companies operating in the hepatic encephalopathy market are actively involved in the development of innovative drugs aimed at treating hepatic encephalopathy. These efforts are driven by the desire to gain a competitive edge and reinforce their market position. For instance, in June 2023, Karolinska Development AB, a Sweden-based pharmaceutical company, introduced the novel GR3027 (golexanolone) for the treatment of hepatic encephalopathy. GR3027 is an orally administered small molecule classified as a GABAA-receptor-modulating steroid antagonist (GAMSA), designed to counteract positive GABAA-receptor modulation by endogenous neuroactive steroids. Additionally, the drug is undergoing clinical trials for the treatment of hepatic encephalopathy, specifically for chronic hepatic encephalopathy (CHE) in Phases I/IIa.

In September 2022, Genfit SA., a France-based biotechnology company, completed the acquisition of Versantis AG for an undisclosed sum. Through this strategic move, Genfit aims to expand its product pipeline to address other liver diseases characterized by unmet medical needs. Versantis, headquartered in Switzerland, is a biotechnology company specializing in the development of drugs for hepatic encephalopathy.

Major companies operating in the hepatic encephalopathy market are Umecrine Cognition AB, Bausch Health Companies Inc., Mallinckrodt Pharmaceuticals, Lupin Limited, Salix Pharmaceuticals, Norgine B.V., Ferring B.V., ASKA Pharmaceutical Co. Ltd., Vedanta Biosciences Inc., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Ochsner Health Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Amneal Pharmaceuticals LLC, Mallinckrodt PLC, Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., ASKA Pharmaceutical Co. Ltd., Norgine B.V.

North America was the largest region in the hepatic encephalopathy market in 2024. The regions covered in hepatic encephalopathy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatic encephalopathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The hepatic encephalopathy market consists of sales of lactulose, neomycin and zinc supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatic Encephalopathy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatic encephalopathy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatic encephalopathy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatic encephalopathy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antibiotics; Laxatives; L-Ornithine; L-Aspartate; Other Drug Classes
• 2) By Route Of Administration: Oral; Intravenous; Rectal
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Antibiotics: Rifaximin; Neomycin; Metronidazole
• 2) By Laxatives: Lactulose; Polyethylene Glycol; Sorbitol
• 3) By L-Ornithine, L-Aspartate: L-Ornithine L-Aspartate
• 4) By Other Drug Classes: Zinc Supplements; Probiotics; Hepatoprotective Agents
• Companies Mentioned: Umecrine Cognition AB; Bausch Health Companies Inc.; Mallinckrodt Pharmaceuticals; Lupin Limited; Salix Pharmaceuticals
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hepatic Encephalopathy Market Characteristics

3. Hepatic Encephalopathy Market Trends And Strategies

4. Hepatic Encephalopathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Hepatic Encephalopathy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hepatic Encephalopathy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hepatic Encephalopathy Market Growth Rate Analysis
• 5.4. Global Hepatic Encephalopathy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hepatic Encephalopathy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hepatic Encephalopathy Total Addressable Market (TAM)

6. Hepatic Encephalopathy Market Segmentation

• 6.1. Global Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Laxatives
• L-Ornithine
• L-Aspartate
• Other Drug Classes
• 6.2. Global Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Rectal
• 6.3. Global Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Hepatic Encephalopathy Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rifaximin
• Neomycin
• Metronidazole
• 6.5. Global Hepatic Encephalopathy Market, Sub-Segmentation Of Laxatives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lactulose
• Polyethylene Glycol
• Sorbitol
• 6.6. Global Hepatic Encephalopathy Market, Sub-Segmentation Of L-Ornithine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• L-Aspartate
• L-Ornithine L-Aspartate
• 6.7. Global Hepatic Encephalopathy Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Zinc Supplements
• Probiotics
• Hepatoprotective Agents

7. Hepatic Encephalopathy Market Regional And Country Analysis

• 7.1. Global Hepatic Encephalopathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hepatic Encephalopathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatic Encephalopathy Market

• 8.1. Asia-Pacific Hepatic Encephalopathy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatic Encephalopathy Market

• 9.1. China Hepatic Encephalopathy Market Overview
• 9.2. China Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatic Encephalopathy Market

• 10.1. India Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatic Encephalopathy Market

• 11.1. Japan Hepatic Encephalopathy Market Overview
• 11.2. Japan Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatic Encephalopathy Market

• 12.1. Australia Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatic Encephalopathy Market

• 13.1. Indonesia Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatic Encephalopathy Market

• 14.1. South Korea Hepatic Encephalopathy Market Overview
• 14.2. South Korea Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatic Encephalopathy Market

• 15.1. Western Europe Hepatic Encephalopathy Market Overview
• 15.2. Western Europe Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatic Encephalopathy Market

• 16.1. UK Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatic Encephalopathy Market

• 17.1. Germany Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatic Encephalopathy Market

• 18.1. France Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatic Encephalopathy Market

• 19.1. Italy Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatic Encephalopathy Market

• 20.1. Spain Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatic Encephalopathy Market

• 21.1. Eastern Europe Hepatic Encephalopathy Market Overview
• 21.2. Eastern Europe Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatic Encephalopathy Market

• 22.1. Russia Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatic Encephalopathy Market

• 23.1. North America Hepatic Encephalopathy Market Overview
• 23.2. North America Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatic Encephalopathy Market

• 24.1. USA Hepatic Encephalopathy Market Overview
• 24.2. USA Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatic Encephalopathy Market

• 25.1. Canada Hepatic Encephalopathy Market Overview
• 25.2. Canada Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatic Encephalopathy Market

• 26.1. South America Hepatic Encephalopathy Market Overview
• 26.2. South America Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatic Encephalopathy Market

• 27.1. Brazil Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatic Encephalopathy Market

• 28.1. Middle East Hepatic Encephalopathy Market Overview
• 28.2. Middle East Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatic Encephalopathy Market

• 29.1. Africa Hepatic Encephalopathy Market Overview
• 29.2. Africa Hepatic Encephalopathy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hepatic Encephalopathy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hepatic Encephalopathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatic Encephalopathy Market Competitive Landscape And Company Profiles

• 30.1. Hepatic Encephalopathy Market Competitive Landscape
• 30.2. Hepatic Encephalopathy Market Company Profiles
  • 30.2.1. Umecrine Cognition AB Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Mallinckrodt Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Lupin Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Salix Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

31. Hepatic Encephalopathy Market Other Major And Innovative Companies

• 31.1. Norgine B.V.
• 31.2. Ferring B.V.
• 31.3. ASKA Pharmaceutical Co. Ltd.
• 31.4. Vedanta Biosciences Inc.
• 31.5. Gilead Sciences Inc.
• 31.6. Amgen Inc.
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Mylan N.V.
• 31.9. Bausch Health Companies Inc.
• 31.10. Ochsner Health Inc.
• 31.11. Sun Pharmaceutical Industries Ltd.
• 31.12. Dr. Reddy's Laboratories Ltd.
• 31.13. Cipla Limited
• 31.14. Amneal Pharmaceuticals LLC
• 31.15. Mallinckrodt Plc

32. Global Hepatic Encephalopathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatic Encephalopathy Market

34. Recent Developments In The Hepatic Encephalopathy Market

35. Hepatic Encephalopathy Market High Potential Countries, Segments and Strategies

• 35.1 Hepatic Encephalopathy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hepatic Encephalopathy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hepatic Encephalopathy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer